Diary - News All news Theranexus announces a new european patent

Theranexus announces a new european patent

Theranexus announces a new european patent protecting THN201 its drug candidate for the treatment of neurocognitive disorders including those associated with alzheimers

Lyon, 9 October 2018 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today that it has received a European patent protecting THN201, its drug candidate for the treatment of neurocognitive disorders including those associated with Alzheimers.